<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00731861</url>
  </required_header>
  <id_info>
    <org_study_id>0412-21/ IUCRO-0101</org_study_id>
    <nct_id>NCT00731861</nct_id>
  </id_info>
  <brief_title>Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors</brief_title>
  <official_title>Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate PTK787, a new oral drug that stops blood vessel development, in
      combination with Paclitaxel in patients with advanced solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of escalating doses of paclitaxel in combination with PTK787</measure>
    <time_frame>Baseline through End of Study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics of paclitaxel alone and in combination with PTK787 from patients with cancer accrued to this study</measure>
    <time_frame>Baseline through End of Study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Neoplasm Metastasis</condition>
  <condition>Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel plus PTK787</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel plus PTK787</intervention_name>
    <description>Paclitaxel will be given on days 1 and 15 over 28 days in cycle 1 with PTK787 on days 3 to 28. PTK787 WILL BE TAKEN AT NIGHT.
In cycle 2 and beyond, paclitaxel will be given on days 1, 8 and 15 every 28 days . PTK787 will be taken orally NIGHTLY.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with histologically confirmed malignancy that is unresponsive to
             curative therapy and for which no conventional therapy exists

          -  ECOG Performance Status 0-2

          -  Measurable or evaluable disease

          -  Laboratory values within protocol limits within 2 weeks prior to registration

          -  Life expectancy ≥ 12 weeks

          -  Patient or guardian must have written informed consent obtained according to local
             guidelines

          -  Women of child-bearing potential (non-sterile) must use appropriate barrier
             contraception for duration of study (negative pregnancy test required at baseline).
             Oral contraceptives will not be an acceptable form of contraception

          -  Patients may have received prior standard taxane therapy, but have never progressed on
             taxane-based therapy.

        Exclusion Criteria:

          -  History or presence of central nervous system (CNS) disease (i.e., primary brain
             tumor, malignant seizures, CNS metastases or carcinomatous meningitis).

          -  Prior chemotherapy ≤ 3 weeks prior to registration. Patients must have recovered from
             all therapy-related toxicities

          -  Prior biologic or immunotherapy ≤ 2 weeks prior to registration. Patients must have
             recovered from all therapy-related toxicities

          -  Prior full pelvic field radiotherapy ≤ 4 weeks or limited field radiotherapy ≤ 2 weeks
             prior to randomization.

          -  Major surgery (i.e., laparotomy) ≤ 4 weeks prior to randomization. Minor surgery ≤ 2
             weeks prior to randomization.

          -  Patients who have received investigational drugs ≤ 4 weeks prior to registration

          -  Prior therapy with anti-VEGF agents

          -  Peripheral neuropathy with functional impairment ≥ CTC grade 2 neuropathy, regardless
             of causality

          -  Pleural effusion or ascites that causes respiratory compromise (≥ CTC grade 2 dyspnea)

          -  Female patients who are pregnant or breast feeding, or adults of reproductive
             potential not employing an effective method of birth control.

          -  Patient agrees to avoid grapefruit (juice and fruit)

        Any of the following concurrent severe and/or uncontrolled medical conditions which could
        compromise participation in the study:

          -  Uncontrolled high blood pressure, history of labile hypertension, or history of poor
             compliance with an antihypertensive regimen

          -  Unstable angina pectoris

          -  Congestive heart failure greater than NYHA classification ≥ Grade 1 (can be controlled
             with medication)

          -  Myocardial infarction ≤ 6 months prior to registration and/or randomization

          -  Serious uncontrolled cardiac arrhythmia

          -  Uncontrolled diabetes at discretion of investigator

          -  Active or uncontrolled infection requiring intravenous antibiotics

          -  Interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung

          -  Patients at risk of QT prolongation such as patients with congenital long QT syndrome
             or with long QTc at baseline (i.e. QTc greater than 450 msec in males, and greater
             than 470 msec in females) will be excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriela Chiorean, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2008</study_first_posted>
  <last_update_submitted>September 10, 2014</last_update_submitted>
  <last_update_submitted_qc>September 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Vatalanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

